This page includes promotional meetings and events organised and funded by Novartis Pharmaceuticals UK Ltd. Novartis products may be mentioned on this page and/or subsequent event pages.
Prescribing information links can be found at the bottom of the page.
Upcoming events
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
27
|
28
|
29
|
30
|
1
|
2
|
3
|
|
4
|
5
|
6
|
7
|
8
|
9
|
10
|
|
11
|
12
|
13
|
14
|
15
|
16
|
17
|
|
18
|
19
|
20
|
21
|
22
|
23
|
24
|
|
25
|
26
|
27
|
28
|
29
|
30
|
31
|
Cardio-metabolic events
Dermatology events
Haematology events
Immunology events
Neuroscience events
Oncology events
Radioligand therapy (RLT) events
Respiratory and inflammation events
Rheumatology events
AIMOVIG® (erenumab) Prescribing information (external link)
COSENTYX® (secukinumab) Prescribing information (external link)
ENTRESTO® (sacubitril/valsartan) Prescribing information (external link)
FABHALTA®▼ (iptacopan) Prescribing information (external link)
ILARIS® (canakinumab) Prescribing information (external link)
JAKAVI® (ruxolitinib) Prescribing information (external link)
KESIMPTA®▼ (ofatumumab) Prescribing information (external link)
KISQALI® (ribociclib) Prescribing information (external link)
LEQVIO® (inclisiran) Prescribing information (external link)
MAYZENT® (siponimod) Prescribing information (external link)
SANDOSTATIN® LAR® (octreotide acetate) Prescribing information (external link)
SCEMBLIX®▼ (asciminib) Prescribing information (external link)
XOLAIR® (omalizumab) Prescribing information (external link)
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
